All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 CEA (F39-11) h(28OXζ), which is constructed for the engineering of T cells to target human CEA. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-CEA antibody linked to a CD28 transmembrane domain/ endodomain and OX40, CD3-zeta signaling domains. And the vector product was designed for the treatment of Pancreatic cancer.
CAR Construction : F39-11 scFv-28ζ Fig.1 Phenotypic analysis of CEA-specific CAR-T cells. CEA-specific CARs on mouse T cells transduced using retroviral vectors were analyzed after staining with biotinylated-CEA followed by staining with anti-CD4C, CD8C, CD62L, and CD127. Both CD4C and CD8C T cells expressed CAR that could bind CEA on the cell surfaces. Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., ... & Shiku, H. (2016). Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology, 5(9), e1211218. |
CAR Construction : F39-11 scFv-28ζ Fig.2 Cytotoxic activity of CEA-specific CAR-T cells against CEA (MC38) and CEAC (MC32a) gastric tumor cell lines in 6-h 51Cr-release assays. The marginal, if any, antitumor effect of CAR-T cells seen in mice that did not receive preconditioning was closely associated with rapid disappearance of transferred CAR-T cells in the peripheral blood. Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., ... & Shiku, H. (2016). Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology, 5(9), e1211218. |
CAR Construction : F39-11 scFv-28ζ Fig.3 Tumor growth curves of mice transferred with CAR-T cells. WT and CEA-Tg mice bearing 7-d-old MC38 or MC32a tumors were transferred with CEA-specific CAR-T cells. Some mice also received lymphodepleting preconditioning as indicated. Tumor volumes were measured by a calliper using the formula (length x width) at the indicated time points (n=5). Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., ... & Shiku, H. (2016). Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology, 5(9), e1211218. |
CAR Construction : F39-11 scFv-28ζ Fig.4 Severe weight loss and the eventual death of CEA-Tg mice transferred with CEA-specific CAR-T cells. Cryostat sections of organs collected from mice at 17 day after tumor inoculation were subjected to CD45.1 immunohistochemistry. Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., ... & Shiku, H. (2016). Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology, 5(9), e1211218. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CEA (F39-11) h(CD28-OX40-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX361). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION